DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL
    1.
    发明申请
    DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL 审中-公开
    使用NGAL诊断和监测慢性肾病

    公开(公告)号:US20100234765A1

    公开(公告)日:2010-09-16

    申请号:US12785237

    申请日:2010-05-21

    IPC分类号: A61B5/00

    摘要: A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

    摘要翻译: 通过检测尿液,血清或血浆中的嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL)的量来评估患有慢性肾损伤或疾病的哺乳动物的正在进行的肾脏状态的方法,包括慢性肾功能衰竭(CRF) 样品在离散的时间段,以及随着时间的推移。 长时间的CRF患者NGAL水平的增加增加是肾脏疾病恶化的诊断。 NGAL的这种增加先于慢性肾病或CRF恶化的其他指标,如血清肌酐升高,尿蛋白分泌增加,肾小球滤过率(GFR)降低。 通过患者治疗前和治疗后的NGAL水平证实,正确检测恶化(或改善,如果治疗已经建立)肾脏状态,可以帮助临床从业者设计和/或维持适当的治疗方案缓慢 或停止CRF的进展。

    DETECTION OF NGAL IN CHRONIC RENAL DISEASE
    2.
    发明申请
    DETECTION OF NGAL IN CHRONIC RENAL DISEASE 审中-公开
    检测慢性肾脏疾病中的NGAL

    公开(公告)号:US20100015648A1

    公开(公告)日:2010-01-21

    申请号:US12567860

    申请日:2009-09-28

    IPC分类号: G01N33/53

    摘要: Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

    摘要翻译: 公开了通过随时间检测流体样品中嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL)的量来评估患有慢性肾功能衰竭(CRF)的受试者正在进行的肾脏状态的方法。 NGAL是一种小分泌的多肽,其是蛋白酶抗性的,因此由于慢性肾小管细胞损伤在尿液和血清中容易检测到。 长时间的CRF患者NGAL水平的增加增加是肾脏疾病恶化的诊断。 NGAL的这种增加先于CRF恶化的其他指标,如增加血清肌酐,增加尿蛋白分泌,降低肾小球滤过率(GFR)。 通过患者治疗前和治疗后的NGAL水平证实,正确检测恶化(或改善,如果治疗已经建立)肾脏状态,可以帮助临床从业者设计和/或维持适当的治疗方案缓慢 或停止CRF的进展。

    DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL
    3.
    发明申请
    DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL 审中-公开
    使用NGAL诊断和监测慢性肾脏病

    公开(公告)号:US20110143381A1

    公开(公告)日:2011-06-16

    申请号:US13025272

    申请日:2011-02-11

    IPC分类号: G01N33/53

    摘要: A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

    摘要翻译: 通过检测尿液,血清或血浆中的嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL)的量来评估患有慢性肾损伤或疾病的哺乳动物的正在进行的肾脏状态的方法,包括慢性肾功能衰竭(CRF) 样品在离散的时间段,以及随着时间的推移。 长时间的CRF患者NGAL水平的增加增加是肾脏疾病恶化的诊断。 NGAL的这种增加先于慢性肾病或CRF恶化的其他指标,如血清肌酐升高,尿蛋白分泌增加,肾小球滤过率(GFR)降低。 通过患者治疗前和治疗后的NGAL水平证实,正确检测恶化(或改善,如果治疗已经建立)肾脏状态,可以帮助临床从业者设计和/或维持适当的治疗方案缓慢 或停止CRF的进展。

    DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL

    公开(公告)号:US20100184089A1

    公开(公告)日:2010-07-22

    申请号:US12750241

    申请日:2010-03-30

    IPC分类号: G01N33/573 G01N33/566

    摘要: A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

    DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL

    公开(公告)号:US20080090304A1

    公开(公告)日:2008-04-17

    申请号:US11770245

    申请日:2007-06-28

    IPC分类号: G01N33/53 G01N33/68

    摘要: A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

    Method for distinguishing between kidney dysfunctions
    6.
    发明授权
    Method for distinguishing between kidney dysfunctions 有权
    区分肾脏功能障碍的方法

    公开(公告)号:US07977110B2

    公开(公告)日:2011-07-12

    申请号:US12143769

    申请日:2008-06-21

    IPC分类号: C12Q1/25 G01N33/53

    摘要: A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

    摘要翻译: 使用与预定的NGAL截止值进行比较的尿液或循环NGAL测定结果来区分哺乳动物的肾功能异常的方法,包括肾前氮血症,可能进展为急性肾衰竭的急性肾损伤和慢性肾脏疾病 水平和单次血清或血浆肌酐测量。 通常,单次肌酐测量不能区分急性肾损伤与慢性肾脏疾病或肾前肾动脉血尿,尿NGAL的单次测量结合单次血清或血浆肌酐测量,具有足够的灵敏度和特异性来区分急性肾损伤与正常功能 ,肾前性氮血症和慢性肾脏疾病,并预测住院结果差。 可以根据尿液或循环NGAL和血清或血浆肌酐的单次测量,对住院急诊部患有任何急性肾损伤,肾上腺氮血症,慢性肾脏疾病或甚至正常肾功能的患者进行评估。 泌尿NGAL水平高度预测临床结果,包括肾脏咨询,透析和入院重症监护病房。

    METHOD FOR DISTINGUISHING BETWEEN KIDNEY DYSFUNCTIONS
    7.
    发明申请
    METHOD FOR DISTINGUISHING BETWEEN KIDNEY DYSFUNCTIONS 有权
    用于辨别KIDNEY功能障碍的方法

    公开(公告)号:US20090298047A1

    公开(公告)日:2009-12-03

    申请号:US12143769

    申请日:2008-06-21

    IPC分类号: C12Q1/25

    摘要: A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.

    摘要翻译: 使用与预定的NGAL截止值进行比较的尿液或循环NGAL测定结果来区分哺乳动物的肾功能异常的方法,包括肾前氮血症,可能进展为急性肾衰竭的急性肾损伤和慢性肾脏疾病 水平和单次血清或血浆肌酐测量。 通常,单次肌酐测量不能区分急性肾损伤与慢性肾脏疾病或肾前肾动脉血尿,尿NGAL的单次测量结合单次血清或血浆肌酐测量,具有足够的灵敏度和特异性来区分急性肾损伤与正常功能 ,肾前性氮血症和慢性肾脏疾病,并预测住院结果差。 可以根据尿液或循环NGAL和血清或血浆肌酐的单次测量,对住院急诊部患有任何急性肾损伤,肾上腺氮血症,慢性肾脏疾病或甚至正常肾功能的患者进行评估。 泌尿NGAL水平高度预测临床结果,包括肾脏咨询,透析和入院重症监护病房。

    DETECTION OF NGAL IN CHRONIC RENAL DISEASE
    8.
    发明申请
    DETECTION OF NGAL IN CHRONIC RENAL DISEASE 审中-公开
    检测慢性肾脏疾病中的NGAL

    公开(公告)号:US20140080155A1

    公开(公告)日:2014-03-20

    申请号:US14088638

    申请日:2013-11-25

    IPC分类号: G01N33/68

    摘要: Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

    摘要翻译: 通过随时间检测流体样品中嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL)的量来评估患有慢性肾功能衰竭(CRF)的受试者正在进行的肾脏状态的方法。 NGAL是一种小分泌的多肽,其是蛋白酶抗性的,因此由于慢性肾小管细胞损伤在尿液和血清中容易检测到。 长时间的CRF患者NGAL水平的增加增加是肾脏疾病恶化的诊断。 NGAL的这种增加先于CRF恶化的其他指标,如增加血清肌酐,增加尿蛋白分泌,降低肾小球滤过率(GFR)。 正确检测恶化(或改善,如果治疗已经建立)肾脏状态随着时间的推移,由患者治疗前和治疗后的NGAL水平证实,可以帮助设计和/或维持适当的治疗方案以减慢或停止 CRF进展。

    DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL

    公开(公告)号:US20130137122A1

    公开(公告)日:2013-05-30

    申请号:US13747646

    申请日:2013-01-23

    IPC分类号: G01N33/68

    摘要: A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.